drugset / Trial / NCT03837808
Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma
Phase 3
Unknown
384 enrolled
Sun Yat-sen University
Affiliated Cancer Hospital & Institute of Guangzhou Medical University · collabFirst Affiliated Hospital, Sun Yat-Sen University · collabGuangdong Provincial People's Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase III trial to study the effectiveness of nimotuzumab versus cisplatin combined with intensity-modulated radiation therapy (IMRT) in treating patients with stage II-III nasopharyngeal carcinoma.
Timeline
- Start
- 2019-04-11
- Primary completion
- 2024-02-11
- Completion
- 2024-02-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cisplatin | Other / unclassified | 40 mg/m2 | — |
| Subject | Nimotuzumab | Monoclonal antibody | 200 mg | — |